HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2023

Khalid Abd-Elghany

Speaker at World Congress on Infectious Diseases 2023 - Khalid Abd-Elghany
Egyption Drug Authority, Egypt
Title : Integration of immunoinformatics and cheminformatics to design and evaluate a multitope vaccine against klebsiella pneumoniae and pseudomonas aeruginosa coinfection


Klebsiella pneumoniae (K. pneumoniae) and Pseudomonas aeruginosa (P. Q25 aeruginosa) are the most common Gram-negative bacteria associated with pneumonia and coinfecting the same patient. Despite their high virulence, there is no effective vaccine against them. In the current study, the screening of several proteins from both pathogens highlighted FepA and OmpK35 for K. pneumoniaein addition to HasR and OprF from P. aeruginosa as promising candidates for epitope mapping. Those four proteins were linked to form a multitope vaccine, that was formulated with a suitable adjuvant, and PADRE peptides to finalize the multitope vaccine construct. The final vaccine’s physicochemical features, antigenicity, toxicity, allergenicity, and solubility were evaluated for use in humans. The output of the computational analysis revealed that the designed multitope construct has passed these assessments with satisfactory scores where, as the last stage, we performed a molecular docking study between the potential vaccine construct and K. pneumoniaein-associated immune receptors, TLR4 and TLR2, showing affinitive to both targets with preferentiality for the TLR4 receptor protein. Validation of the docking studies has proceeded through molecular dynamics simulation, which estimated a strong binding and supported the nomination of the designed vaccine as a putative solution for K. pneumoniae and P. aeruginosa coinfection. Here, we describe the approach for the design and assessment of our potential vaccine.


Khalid Abd-Elghany studied Pharmaceutical Science at Al Azha University,Egypt and graduated as MS of Microbial Biotechnology in 2014 from El Sadat city Univerisity, Egypt . Ph.D,  of Microbial Biotechnology from El Sadat city Univerisity, Egypt 2018.